Found: 17
Select item for more details and to access through your institution.
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 2, p. 252, doi. 10.1016/j.clgc.2023.11.007
- By:
- Publication type:
- Article
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 19, p. 3674, doi. 10.1002/cam4.4743
- By:
- Publication type:
- Article
Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 539, doi. 10.1002/cam4.4443
- By:
- Publication type:
- Article
Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
- Published in:
- Radiation Oncology, 2021, v. 16, n. 1, p. 1, doi. 10.1186/s13014-021-01937-9
- By:
- Publication type:
- Article
Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, p. 1, doi. 10.1186/s13046-018-0695-5
- By:
- Publication type:
- Article
FXR1 can bind with the CFIm25/CFIm68 complex and promote the progression of urothelial carcinoma of the bladder by stabilizing TRAF1 mRNA.
- Published in:
- Cell Death & Disease, 2022, v. 13, n. 2, p. 1, doi. 10.1038/s41419-022-04614-1
- By:
- Publication type:
- Article
Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate.
- Published in:
- Biomaterials Research, 2022, v. 26, n. 1, p. 1, doi. 10.1186/s40824-022-00328-9
- By:
- Publication type:
- Article
Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA.
- Published in:
- Biomaterials Research, 2022, v. 26, n. 1, p. 1, doi. 10.1186/s40824-022-00251-z
- By:
- Publication type:
- Article
Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Correction: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21.
- Published in:
- Cancer Science, 2021, v. 112, n. 5, p. 1758, doi. 10.1111/cas.14810
- By:
- Publication type:
- Article